ORBIMED ADVISORS LLC 13D and 13G filings for Gracell Biotechnologies Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-08-11 4:23 pm Purchase | 2023-08-10 | 13D | Gracell Biotechnologies Inc. GRCL | ORBIMED ADVISORS LLC | 7,641,531 8.000% | 57,955 (+0.76%) | Filing |
| 2023-03-31 4:48 pm Purchase | 2023-03-29 | 13D | Gracell Biotechnologies Inc. GRCL | ORBIMED ADVISORS LLC | 7,583,576 11.200% | 1,612,904 (+27.01%) | Filing |
| 2023-02-14 4:20 pm Unchanged | 2022-12-31 | 13G | Gracell Biotechnologies Inc. GRCL | ORBIMED ADVISORS LLC | 5,970,672 8.800% | 0 (Unchanged) | Filing |
| 2022-02-11 4:23 pm Sale | 2021-12-31 | 13G | Gracell Biotechnologies Inc. GRCL | ORBIMED ADVISORS LLC | 5,970,672 8.900% | -23,882,692 (-80.00%) | Filing |
| 2021-01-21 4:46 pm Purchase | 2021-01-12 | 13D | Gracell Biotechnologies Inc. GRCL | ORBIMED ADVISORS LLC | 29,853,364 9.100% | 29,853,364 (New Position) | Filing |